TOP TIERMARKET NEWSWIRE

News & sentiment

IMUNON INC (IMNN) — News & AI sentiment

IMUNON INC (IMNN) news roundup. 3 stories in the past week, 13 over 30 days. Average 30-day sentiment is 46.2/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 3 sales totalling $12K — net selling of $12K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

3

avg sentiment 44.7/100

30d stories

13

avg sentiment 46.2/100

Insider net (90d)

$12K

0 buys · 3 sells

Congress (90d)

0

0 buys · 0 sells

IMNN news in the last 24 hours, 7 days, 30 days and 90 days

How much IMNN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	IMNN stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	3	44.7/100	IMNN headlines →
Last 30 days	13	46.2/100	IMNN headlines →
Last 90 days	36	53.8/100	IMNN headlines →

Latest stories on IMNN

Imunon files to sell 20M shares of common stock, pre-funded warrants

The Fly26 · bearishgeneral

1d ago

Imunon, Inc. (IMNN) files 8-K

SEC 8-K50 · neutralgeneral

2d ago

Imunon Divests ThermoDox Assets to VoxelDox Therapeutics

TipRanks54 · neutralm&a

Oct 21

Imunon to sell ThermoDox rights to VoxelDox Therapeutics for ownership stake

The Fly58 · neutralm&a

Oct 21

Imunon, Inc. (IMNN) files 8-K

SEC 8-K53 · neutralgeneral

Oct 21

IMUNON Announces Strategic Sale of ThermoDox®

Business Insider58 · neutralm&a

Oct 21

IMUNON Announces Strategic Sale of ThermoDox®

GlobeNewswire58 · neutralm&a

Oct 21

IMUNON to Participate in Upcoming Investor Conferences

Business Insider52 · neutralproduct/pr

Oct 8

IMUNON to Participate in Upcoming Investor Conferences

GlobeNewswire52 · neutralproduct/pr

Oct 8

Imunon Introduces Series B Preferred to Restructure Debt

TipRanks34 · bearishgeneral

Sep 29

Imunon, Inc. (IMNN) files 8-K

SEC 8-K50 · neutralgeneral

Sep 29

IMUNON Converts $1.2 Million of Debt-to-Equity

GlobeNewswire28 · bearishgeneral

Sep 29

IMUNON Converts $1.2 Million of Debt-to-Equity

StockTitan28 · bearishgeneral

Sep 29

Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow

Seeking Alpha50 · neutralgeneral

Sep 24

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

Business Insider69 · bullishproduct/pr

Sep 24

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

GlobeNewswire67 · bullishproduct/pr

Sep 24

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript

Seeking Alpha50 · neutralgeneral

Sep 23

Imunon announces IDMC recommends continued Phase 2 development of IMNN-001

The Fly63 · neutralproduct/pr

Sep 22

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Business Insider67 · bullishproduct/pr

Sep 22

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

GlobeNewswire67 · bullishproduct/pr

Sep 22

Imunon enters CRADA with National Cancer Institute for IMNN-001 development

The Fly63 · neutralproduct/pr

Sep 10

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

GlobeNewswire67 · bullishproduct/pr

Sep 10

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Business Insider63 · neutralproduct/pr

Sep 10

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

GlobeNewswire56 · neutralproduct/pr

Sep 9

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

Business Insider56 · neutralproduct/pr

Sep 9

Open IMNN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →